STING1 and breast cancer: Particularly, paclitaxel has been closely associated with the activation of the cGAS-STING pathway in breast cancer treatment (Zhu C. et al., 2022; Qiu et al., 2022), suggesting that targeting this pathway offers a novel approach for treating breast cancer.